Can a device that stimulates cell activity using radio electric emissions improve recovery from traumatic joint injuries?
| ISRCTN | ISRCTN24138677 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN24138677 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | UNIFAP-IRF-02-19 |
| Sponsors | Federal University of Amapá, Rinaldi Fontani Institute and Foundation |
| Funder | Investigator initiated and funded |
- Submission date
- 20/09/2019
- Registration date
- 30/09/2019
- Last edited
- 07/09/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Plain English summary of protocol
Background and study aims
It is thought that that physical injury can lead to changes that the injured person is not aware of, which involve psychological and emotional responses, and result in changes to how the person moves the affected limb. This can slow rehabilitation and prevent complete recovery from the injury.
It is possible that radio and electric stimulation of the nerves and tissues could help to reduce recovery time. This study aims to investigate this.
Who can participate?
Adults aged 18-70 years with an injury to the medial collateral ligament (MCL) of the knee that has been diagnosed no more than 4 days previously
What does the study involve?
The radio and electrical stimulation is delivered using the REAC device. On the first treatment day, the device was applied to the ear. Over the next 2 weeks, the participants received 18 treatments with the device probe applied to the injured area. Participants were assessed before the first treatment, after the last treatment and at 30 days after the last treatment. They agreed not to use any other treatment for their knee injury, including medicines and physiotherapy, during the study or to consult the researchers before using any other treatment.
What are the possible benefits and risks of participating?
Participants might benefit from REAC treatments in reduced pain reduction and healing time, without using drugs. REAC treatments have not previously shown any risk or adverse side effects. The study supervisor will monitor the participants and assess the situation if any physical or psychological harm occurs.
Where is the study run from?
The Federal University of Amapá (Brazil)
When is the study starting and how long is it expected to run for?
November 2018 to July 2019
Who is funding the study?
There was no additional funding required. The Rinaldi Fontani Institute & Foundation (Italy) provided the REAC devices.
Who is the main contact?
Dr. Prof. Ana Rita Pinheiro Barcessat, ritabarcessat@gmail.com
Contact information
Scientific
Universidade Federal do Amapá Rodovia JK, s/n – Bairro Marco Zero do Equador
Macapá
68900-000
Brazil
| 0000-0002-5261-6435 | |
| Phone | 9681334223 |
| ritabarcessat@gmail.com |
Public
Universidade Federal do Amapá Rodovia JK, s/n – Bairro Marco Zero do Equador
Macapá
68900-000
Brazil
| 0000-0002-5261-6435 | |
| Phone | 9681334223 |
| ritabarcessat@gmail.com |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Non-randomised non-masked non-controlled study |
| Secondary study design | Non randomised study |
| Participant information sheet | ISRCTN24138677_PIS_26Sep2019.pdf |
| Scientific title | Neurobiological modulation using the Radio Electric Asymmetric Conveyer (REAC) to improve recovery in acute post-trauma joint injuries |
| Study acronym | REACTJIR |
| Study objectives | Physical traumas can lead to unconscious neuropsychic alterations which can compromise the rehabilitation result and complete functional recovery. Radioelectric asymmetric conveyor (REAC) neurobiological treatments Neuro Postural Optimization (NPO) and Tissue Optimization (TO) are able respectively to improve neuropsychomotor strategies and the neuropsychophysical response to trauma, and facilitate the recovery process in damaged tissues. The combined use of REAC NPO and TO can envisage a new rehabilitative approach, which aims not only at recovering the outcomes of the physical trauma but also at improving the neuropsychic state that can condition complete recovery. |
| Ethics approval(s) | Approved 02/04/2019, Ethics Committee of the Federal University of Amapá (Rodovia Juscelino Kubitscheck de Oliveira, Macapá, Brasil; +55 96 4009-2805; cep@unifap.br), ref: 3.238.424 |
| Health condition(s) or problem(s) studied | Post-traumatic knee medial collateral ligament lesion |
| Intervention | 50 outpatients with acute post-traumatic knee medial collateral ligament lesion in care at Health Sciences Department of the Federal University of Amapá, Macapá – Brazil were enrolled for this single-centre study, without randomization, masking, control, and assignment. The REAC technology device used in this clinical investigation was a model BENE 110 (ASMED, Florence, Italy). The study was conducted administering 2 treatments with the REAC device: the Neuro Postural Optimization (NPO) and the Tissue Optimization (TO). Within 4 days after the trauma, 50 subjects were enrolled, but only 45 subjects completed the study. These 45 subjects (23 with grade 3 Medial Collateral Lesion and 22 with grade 2 MCL lesion) were clinically evaluated (T0), both through the medical and the subjective assessments, about pain, swelling, functional impotence, feeling of knee instability, instability to monopodalic load and functional dysmetria. Clinical evaluation was repeated after the REAC NPO treatment (T1) and at the end of 18 REAC TO treatments (T2) and at the 30 days follow-up (T3). The NPO consists of a single treatment of few milliseconds administered on a specific area of the auricle pavilion, while the TO treatment is administered by applying the device's asymmetric conveyer probe (ACP), to the area to be treated. The duration of the TO treatment is some minutes. The administration of the 18 TO treatments was carried out over the two-week maximum from the traumatic event. |
| Intervention type | Device |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | |
| Primary outcome measure(s) |
Time to healing, with healing assessed using the following assessments by the medical practitioner and subjective assessments of the patient at the first clinical examination, within 4 days after the trauma/accident (T0); immediately after the administration of the Neuro Postural Optimization (NPO) treatment, which is the one-session treatment delivered on the subject’s ear (T1); at the end of the 18th session of Tissue Optimization (TO) treatment (T2); at the 30 day-follow up (T3): |
| Key secondary outcome measure(s) |
Pain reduction in post-traumatic second and third-degree lesions of the medial collateral ligament of the knee evaluated with verbal analogue scale none (1), little (2), very (3), very much (4) at the first clinical examination, within 4 days after the trauma/accident (T0); immediately after the administration of the Neuro Postural Optimization (NPO) treatment, which is the one-session treatment delivered on the subject’s ear (T1); at the end of the 18th session of Tissue Optimization (TO) treatment (T2) and at the 30 day-follow up (T3) |
| Completion date | 30/07/2019 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 70 Years |
| Sex | All |
| Target sample size at registration | 50 |
| Total final enrolment | 45 |
| Key inclusion criteria | 1. Aged 18-70 years 2. Diagnosed using MRI or ultrasound with a grade 3 or 2 injury to the medial collateral ligament of the knee 3. Diagnosed no more than 4 days before the day of enrolment in the study |
| Key exclusion criteria | Previous other joint disorders of the affected knee |
| Date of first enrolment | 29/04/2019 |
| Date of final enrolment | 10/05/2019 |
Locations
Countries of recruitment
- Brazil
- Italy
Study participating centres
Macapà
68900-000
Brazil
Firenze
50144
Italy
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| IPD sharing plan | The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/07/2020 | 07/09/2020 | Yes | No |
| Participant information sheet | 26/09/2019 | 08/10/2019 | No | Yes | |
| Participant information sheet | 26/09/2019 | 08/10/2019 | No | Yes | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Additional files
- ISRCTN24138677_PIS_26Sep2019.pdf
- uploaded 08/10/2019
- ISRCTN24138677_PIS_26Sep2019_English version.pdf
- uploaded 08/10/2019
Editorial Notes
07/09/2020: The following changes have been made:
1. Publication reference added.
2. The final enrolment number has been added from the reference.
08/10/2019: The participant information sheet has been uploaded as two additional files (original version in Portuguese, and English translation)
26/09/2019: Trial's existence confirmed by the Ethics Committee of the Federal University of Amapá (UNIFAP).